MedTrace Logo

Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis

NCT03048383 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2017-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness of three commercially available botulinum toxin neuromodulators in the treatment of facial synkinesis using patient reported outcome measures.

Conditions

  • Facial Nerve Injuries
  • Facial Paresis Associated With Facial Nerve Dysfunction
  • Facial Asymmetry
  • Synkinesis

Interventions

DRUG

OnabotulinumtoxinA Injectable Product

Administered to treat facial synkinesis

DRUG

AbobotulinumtoxinA Injectable Product

Administered to treat facial synkinesis

DRUG

Incobotulinumtoxin A Injectable Product

Administered to treat facial synkinesis

Sponsors & Collaborators

Principal Investigators

  • Preston D Ward, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03048383 on ClinicalTrials.gov